Evidence map›Paper›PMID 40867302›Full record

ArticleCancers2025

Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.

Imran Nizamuddin, Tarik Demir, Katrina Dobinda, Ruohui Chen, Masha Kocherginsky, Peter Doukas, Neelima Katam, Carolyn Moloney, Devalingam Mahalingam

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Imran NizamuddinRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Tarik DemirDivision of Hematology and Oncology, Developmental Therapeutics Institute, Northwestern University, Chicago, IL 60611, USA.
Katrina DobindaPreventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0009-0002-1148-0540
Ruohui ChenPreventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Masha KocherginskyPreventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Peter DoukasRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Neelima KatamRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Carolyn MoloneyDivision of Hematology and Oncology, Developmental Therapeutics Institute, Northwestern University, Chicago, IL 60611, USA.
Devalingam MahalingamDivision of Hematology and Oncology, Developmental Therapeutics Institute, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0002-2979-9894

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
NCI NIH HHS P30 CA060553
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

genetic mutationsimmune checkpoint inhibitorsliver metastasispredictive biomarkerssolid tumorstumor mutational burden

Identifiers

PMID40867302
PMCPMC12384169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.